Beckerman-Hsu, Jacob P.
Aftosmes-Tobio, Alyssa
Gavarkovs, Adam
Kitos, Nicole
Figueroa, Roger
Kalyoncu, Z. Begum
Lansburg, Kindra
Yu, Xinting
Kazik, Crystal
Vigilante, Adrienne
Leonard, Jessie
Torrico, Merieka
Jurkowski, Janine M.
Davison, Kirsten K. http://orcid.org/0000-0002-3492-918X
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK108200, T32DK007703, T32DK007703)
Article History
Received: 11 February 2020
Accepted: 2 July 2020
First Online: 23 July 2020
Ethics approval and consent to participate
: The process evaluation for CHL, along with the main trial, was initially approved by the Institutional Review Board at the Harvard T.H. Chan School of Public Health. It was approved again by the Institutional Review Board at Boston College when the study team relocated to this university (June 19, 2019). All participants provide written consent before completing study surveys or activities. Participants are informed that de-identified data collected by the Head Start agencies may be used for quality improvement or research purposes and can opt out. Passive consent is used for data sharing between the Head Start agencies and the study team.
: Not applicable.
: The authors declare that they have no competing interests.